Litigation support – a global pharma company abandoned a product launch following unfavorable clinical trial results. When their stock price fell, they were sued for allegedly concealing product information. The court accepted CRA’s analysis and conclusion that the alleged information concealment was an unlikely reason for the price change.

Stakeholder engagement – support for the UK affiliate of a top ten pharma company in a series of HTAs led to aligned and strategic engagement of internal and external influencers. This contributed to positive reimbursement decisions by NICE to ensure access to innovative new medicines.

Multi-stakeholder alignment – support for the UK affiliate of a top ten pharma company in a series of HTAs led to aligned and strategic engagement of internal and external influencers. This contributed to positive reimbursement decisions by NICE to ensure access to innovative new medicines.

Policy analysis – a global pharma company sought insight into the policy implications of variations in access to Multiple Sclerosis treatments across Europe. CRA’s analysis and report has helped the company build its argumentation to policy makers around barriers to effective MS treatment.

HTA impact analysis – EFPIA & PhRMA asked CRA to describe how HTA systems are evolving and their impact on access to medicines in a range of markets. The study demonstrated that HTAs are increasingly delivered in a more timely fashion but are not enabling earlier access to innovative medicines.

Reimbursement policy – CRA reviewed reimbursement of orphan medicines across Europe for a pharma company supplying therapies in this sector. A toolkit on reimbursement practices at national, regional and local levels, set out best and worst practices and their consequences, to support argumentation with payers.

Competitive strategy – a leading pharma company was concerned about the impact of biosimilars in its key therapeutic categories. CRA coordinated the development and implementation of risk mitigation strategies across the client’s teams and that were subsequently integrated into brand plans.

Market access strategy – a top biotech firm was developing a global market access approach for a new therapy in an orphan disease with commoditized first-generation options. CRA conducted simulation workshops to gauge likely competitive response, and helped the client customize its strategy across key geographies.

"Life Sciences"

Life Sciences

CRA helps pharmaceutical, biotechnology, and medical devices companies achieve optimum performance across key aspects of their business including innovation, commercial success, organization, and reputation, all for the long-term benefit of patients, clinicians, employees, and shareholders. We work with life sciences businesses directly as well as with their legal counsel, industry associations, government organizations, and advocacy groups.

Comprehensive, integrated expertise

Why clients value CRA

CRA brings clarity and solutions to complex challenges. Clients turn to us when they need to make the right decision, implement it the right way, and secure buy-in from key stakeholders. Their trust in us is rooted in our emphatic focus on clients and their needs:

Decades of hands-on life sciences experience
Dedicated specialist life sciences team
In-depth sector knowledge, from R&D to market entry and beyond
Strong academic credentials in science, economics, and business
Longstanding client relationships
Analytical rigor and deep insights, enabling better decisions that drive sustainable outcomes
Creative solutions backed by tactical support in execution
Buy-in based on genuine engagement with key stakeholders
Partnership with clients, working with them not for them

The CRA life sciences team operates from offices across the United States and Europe to provide insights on global issues and local market knowledge as well as ease of access for our clients.